This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
DAIS trial and the CARE trial).

Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Three large-scale trials were included in the analysis.
Methods of combining primary studies
The authors referred to a published study that had combined the three primary studies.
Investigation of differences between primary studies
Results of the review
The absolute risk of CHD events over 5 years was 15%.
The absolute risk reduction with fibrate treatment was 7.6% in the VA-HIT trial.
The absolute risk reduction with statin treatment was 2.7% in the CARE trial and 5.5% in the combined 4S, CARE and LIPID trials.
Methods used to derive estimates of effectiveness
The authors made several assumptions about the effectiveness estimates, considering low-, medium-and high-risk reduction scenarios for the absolute risk reduction.
Estimates of effectiveness and key assumptions
The 7.6% absolute risk reduction for fibrate treatment was compared with three alternative scenarios for statin treatment: a low-risk reduction scenario of a 2.7% absolute risk reduction, a medium-risk reduction scenario of a 5.5% absolute risk reduction, and a high-risk reduction scenario of a 7.6% absolute risk reduction.
A further analysis used an 8.1% absolute risk reduction for statin treatment versus an 8.0% reduction for fibrate treatment.
Measure of benefits used in the economic analysis
The incremental savings of fibrate treatment compared with statin treatment were 920,116 for the low-risk scenario, 863,124 for the medium-risk scenario and 820,410 for the high-risk scenario (a 54% reduction in annual cost).
Synthesis of costs and benefits
The synthesis of the costs and benefits was not applicable in the base-case analysis because fibrate treatment was more effective and less costly than statin treatment.
The sensitivity analyses showed that a 13.2% absolute risk reduction was needed for pravastatin to be as cost-effective as fenofibrate.
In addition, pravastatin and simvastatin would need to be associated with an absolute risk reduction rate of 9.8% to be equally cost-effective as fenofibrate.
Authors' conclusions
Fibrate treatment was more cost-effective than statin therapy in patients with Type 2 diabetes.
CRD COMMENTARY -Selection of comparators
A justification was given for the comparators used (no treatment and statin treatment). Statin treatment was chosen as a comparator on the basis of the NICE guidelines for the management of lipids in Type 2 diabetes. You should consider whether this is a widely used technology in your own setting.
Validity of estimate of measure of effectiveness
The principal input parameters for the model were derived from a published study combining three primary studies. Hence, the review was not conducted systematically to identify relevant research and minimise biases. However, the study design of the three primary studies (randomised controlled trials) was appropriate for the study question. The estimates were investigated through sensitivity analyses, using what appear to have been appropriate ranges. Given that a systematic review of the literature was not undertaken, it is difficult to assess the validity of the effectiveness estimates used in the model.
Validity of estimate of measure of benefit
The benefit measure was derived directly from the effectiveness analysis. The authors highlighted that the benefit measure of CHD events avoided was linked to clinical end points rather than lipid end points.
Validity of estimate of costs
The authors limited the estimation of costs to the NHS perspective. However, a societal perspective would have been more appropriate. The costs and the quantities were not reported separately. In addition, only limited details of the cost of treating CHD events were given. Consequently, there is uncertainty as to whether all the relevant costs were included in the analysis. Sensitivity analyses were conducted on these costs. Since the time horizon of the model was 5 years, discounting was appropriately undertaken and a sensitivity analysis on the discount rate was performed. The reader should decide whether the time horizon for evaluating the effects was sufficient. The price year was reported, which will aid any future reflation exercises. The authors reported the incremental cost-effectiveness ratio (ICER). However, because fenofibrate was both more effective and less costly than pravastatin, the ICER was not relevant and may be confusing.
Other issues
The generalisability of the results was not discussed. The authors made appropriate comparisons of their findings with those from other studies. The authors do not appear to have reported their results selectively and did not report further limitations of their study. The results presented appear to be within the scope of the analysis undertaken.
